Sumitomo Dainippon Pharma Annual Report 2017

23No. of employees teaching courses20/1,800Schools using DSP visiting lectures / No. of attendees•Our Policy on Social Contribution Activities•Stakeholder Engagement•Stakeholder Dialogue (see p. 18, 32, 38, 45, 53)•Initiatives for Global Health (see p. 5, 18, 56)•Support through Employee Participation (see p. 38, 57, 58)•Support through Donation•Social Support (see p. 57)•Activities of Global Group Companies (see p. 38, 58)Major Items Reported on Our WebsiteCSR ManagementCommunity Involvement and DevelopmentProviding Learning Opportunities Leveraging Our Strengths as a Pharmaceutical CompanySince 2012, we have been providing visiting lectures at junior high and high schools. This allows us to provide learning opportunities that enable children who will shape the future to grow in good health and exercise their potential to the fullest.These visiting lectures cover topics on DNA diagnostics. After employees give an explanation of genetics, students watch a DVD presenting a hypothetical story in which a DNA diagnosis can indicate whether or not one will develop an incurable disease in the future. Students discuss in groups whether they would have such a diagnosis, and then share their thoughts with the lecturers. The objective of the program is to have students practice being receptive to the opinions of others with regard to topics on life and ethics that do not have clear right or wrong answers, while also fostering the ability to come to one’s own conclusions.These activities to date have garnered praise and received the Encouragement Award in the large corporation category of the Ministry of Economy, Trade and Industry’s 7th Career Education Award.Supporting the Japan Epilepsy Research FoundationEstablished to commemorate the 90th anniversary of the former Dainippon Pharmaceutical Co., Ltd., the Japan Epilepsy Research Foundation (JERF) works to promote research on treatments in the field of epilepsy, while contributing to the health and healthcare of the public, and runs on contributions from Sumitomo Dainippon Pharma and donors. The Foundation provides grants and commendations related to epilepsy. In fiscal 2016, JERF provided 12 research grants, two overseas study grants, and two Japan Epilepsy Research Grants for Inviting Overseas Researchers to Japan. Sumitomo Dainippon Pharma will continue to contribute to the improvement of healthcare and welfare through its support of the Japan Epilepsy Research Foundation.schoolsattendees*Page numbers refer to those in this pamphlet57Sumitomo Dainippon Pharma Co., Ltd. Annual Report 2017

元のページ  ../index.html#58